End-stage Heart Failure
Conditions
Brief summary
Implanting a ventricular assist device (VAD) is a promising therapy for end-stage cardiac failure. However, the implantation of these devices is associated with a high risk of severe hemorrhages and massive blood product transfusion in the first 48 hours following the implantation. The primary purpose of this study is to assess the functionality of the von Willebrand Factor (vWF) which is essential for hemostasis. The hypothesis is that the high shear stress generated by these VAD expose ADAMTS13 cleaving site on the vWF. This result in a loss of high molecular weight vWF and an acquired von Willebrand syndrome. The secondary purpose of the protocol is to assess platelet function after the implantation of VAD. Indeed, platelet function might be affected shortly after the implantation of the device.
Interventions
DEVICEventricular assist device implantation
Blood sampling in patients under surgery for ventricular assist device implantation at five time points: * After anesthetic induction * Before starting the device * 2h, 6h and 48h after starting the device
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years old * Who gave his consent to the study * With an end-stage heart-failure * Under surgery for a ventricular assist device implantation * Scheduled or in emergency
Exclusion criteria
* Preoperative anemia less than 7 g/dL * Subject under the protection of justice * Subject under guardianship or curatorship * Pregnancy * Breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Von Willebrand Factor activity | From Baseline to 48 hours | Change of Von Willebrand Factor from Baseline to 48 hours |
Countries
France
Outcome results
None listed